期刊文献+

负性协同刺激分子PD-1在重症肌无力患者外周血中的表达 被引量:4

Expression of programmed death-1 in peripheral blood of myasthenia gravis patients
原文传递
导出
摘要 目的 观察重症肌无力(MG)患者外周血中负性协同刺激分子programmed death-1( PD-1)的表达情况,并探讨其与MG发病的关系。方法 采用免疫荧光标记、流式细胞仪检测45例MG患者和33名健康对照者外周血单个核细胞中PD-1及其配体PD-L1的表达,用ELISA法检测各组血浆中可溶性PD-1的水平。结果 (1)MG患者表达PD-1的CD4^+T淋巴细胞比例增加,CD14^+PD-L1^+的单核细胞比例增加,但在不同性别及眼肌型与全身型间差异无统计学意义;在胸腺异常MG患者中CD4^+PD-1^+T细胞增加,CD14^+ PD-L1^+的单核细胞比例减少;早发型MG患者(年龄<40岁)CD4^+PD-1^+T淋巴细胞比例明显低于晚发型(年龄≥40岁)。(2)MG患者血浆中sPD-1浓度为(6.92 +0.72) ng/ml,明显高于健康对照组的(3.28±0.42) ng/ml,但在性别、MG眼肌型与全身型不同类型间和有无胸腺异常各组间差异无统计学意义,且sPD-1与发病年龄呈负相关(r=-0.526,P=0.000)。结论 PD-1及PD-L1途径参与了MG的发病,异常升高的sPD-1可能干扰了正常的细胞膜上PD-1与PD-L1的结合,从而促使疾病进展。 Objective To explore the relationship between the negative co-inhibitor programmed death-1 ( PD-1 ) and the pathogenesis of myasthenia gravis ( MG), by detecting the expression of PD-1 and programmed death ligand-1 ( PD-L1 ) on peripheral blood mononuclear cells (PBMCs) and soluble PD-1 (sPD-1) in plasma from myasthenia gravis patients. Methods Peripheral blood samples were collected from 45 MG patients and 33 healthy persons without prednisone or other immunodepressant treatment during the half year ahead of withdrawal. The expression of PD-1 and PD-L1 on PBMCs were detected using immuno-fluorescence labeling and flow cytometry, and the concentrations of sPD-1 in plasma were measured using an ELISA kit. Results(1) The proportion of CD4^+ PD-1^+ T cells, as well as CD14^+ PD-L1^+monocytes of the MG group was higher than that of the control group. There were no significant differences in the proportion of CD4^+ PD-1^+ T cells or CD14^+ PD-L1^+ monocytes in the MG sub-groups between different genders or MG types. While the proportion of CD4^+ PD-1^+ T cells of the late-onset MG (age ≥40) group was higher than that of the early-onset MG group (age 〈40). And it was higher in the MG patients with thymoma or thymus hyperplasia than that from the MG patients with normal thymus. The proportion of CD14^+ PD-L1^+monocytes from the MG patients with thymoma or thymus hyperplasia group decreased obviously compared with that of the patients with normal thymus group; but no difference could be found between the late-onset group and early-onset group. (2)The concentration of sPD-1 in the plasma from the group of MG patients was(6. 92 ±0. 72) ng/ml,which was higher than that of the healthy control group ( (3.28 ±0. 42) ng/ml),even more, it was significantly higher in the early-onset MG group than that of the late-onset MG group,there was a negative correlation( r =-0. 526, P =0. 000) between the age of onset and the concentration of sPD-1. Conclusio
出处 《中华神经科杂志》 CAS CSCD 北大核心 2011年第10期694-697,共4页 Chinese Journal of Neurology
基金 国家自然科学基金资助项目(30800997) 江苏省普通高校研究生科研创新计划(CXLX11_0077)
关键词 重症肌无力 抗原 CD 凋亡调节蛋白质类 Myasthenia gravis Antigens,CD Apoptosis regulatory proteins
  • 相关文献

参考文献19

  • 1Milani M,Ostlie N,Wang W,et al.T cells and cytokines in the pathogenesis of acquired myasthenia gravis.Ann N Y Acad Sci,2003,998:284-307. 被引量:1
  • 2Chambers CA.The expanding world of co-stimulation:the two-signal model revisited.Trends Immunol,2001,22:217-223. 被引量:1
  • 3Okazaki T,Honjo T.PD-1 and PD-1 ligands:from discovery to clinical application.Int Immunol,2007,19:813-824. 被引量:1
  • 4Jaretzki A,Barohn RJ,Emstoff RM,et al.Myasthenia gravis:recommendations for clinical research standards. Neurology,2000,55:16-23. 被引量:1
  • 5吴海竞,陈永井,苗瞄,张光波,胡玉敏,明志君,张学光.可溶性PD-1酶联检测试剂盒的研制及其应用[J].中国免疫学杂志,2008,24(9):825-827. 被引量:2
  • 6Nishimura H,Agata Y,Kawasaki A,et al. Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes.Int Immunol,1996,8:773-780. 被引量:1
  • 7Nielsen C,Ohm-Laursen L,Barington T,et al.Alternative splice variants of the human PD-1 gene.Cell Immunol,2005,235:109-116. 被引量:1
  • 8Riley JL.PD-1 signaling in primary T cells.Immunol Rev,2009,229:114-125. 被引量:1
  • 9Selenko-Gebauer N, Majdic O,Szekeres A,et al. B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy.J Immunol,2003,170:3637-3644. 被引量:1
  • 10Brown JA,Dorfman DM,Ma FR,et al.Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.J Immunol,2003,170:1257-1266. 被引量:1

二级参考文献20

  • 1Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology, 2000, 55 : 16-23. 被引量:1
  • 2Remes-Troche JM, Tellez-Zenteno JF, Estanol B, et al. Thymectomy in myasthenia gravis: response, complications, and associated conditions. Arch Med Res, 2002, 33: 545-551. 被引量:1
  • 3Monden Y, Nakahara K, FujiiY, et al. Myasthenia gravis in elderly Patients. Ann Thorac Surg, 1985, 39: 433-436. 被引量:1
  • 4Taguchi T, Suehiro T, Tom K, et al. Pleural dissemination of thymoma showing tumor regression after combined corticosteroid and tacrolimus therapy. Eur J Intern Med, 2006, 17: 575-577. 被引量:1
  • 5Sempowski G, Thomasch J, Gooding M, et al. Effect of thymectomy on human peripheral blood T cell pools in myasthenia gravis. J Immunol, 2001, 166: 2808-2817. 被引量:1
  • 6Blossom GB, Ernstoff RM, HoweUs GA, et al. Thymectomy for myasthenia gravis. Arch Surg, 1993, 128: 855-862. 被引量:1
  • 7Evoli A, Batocchi AP, Provenzano C, et al. Thymectomy in the treatment of myasthenia gravis; report of 247 patients. J Neurol, 1988, 235: 272-276. 被引量:1
  • 8Wekerle H.The thymus in myasthenia gravis.Ann N Y Acad Sci,1993,681:47-55. 被引量:1
  • 9Palace J, Vincent A, Beeson D.Myasthenia gravis: diagnostic and management dilemmas. Curr Opin Neurol, 2001,14:583-589. 被引量:1
  • 10Gautel M, Lakey A, Barlow DP, et al. Titin antibodies in myasthenia gravis:identification of a major immunogenic region of titin.Neurology ,1993,43:1581-1585. 被引量:1

共引文献11

同被引文献17

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部